Evidence map›Paper›PMID 35443861›Full record

ArticleCancer biology & therapy2022

Real-time luminescence enables continuous drug-response analysis in adherent and suspension cell lines.

Clayton M Wandishin, Charles John Robbins, Darren R Tyson, Leonard A Harris, Vito Quaranta

Abstract read
In one paragraph

Article in Cancer biology & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Clayton M WandishinDepartment of Biochemistry, Vanderbilt University, Nashville, TN USA.ORCID 0000-0002-6779-7451
Charles John RobbinsDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN USA.
Darren R TysonDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN USA.
Leonard A HarrisDepartment of Biomedical Engineering, University of Arkansas, Fayetteville, AR USA.
Vito QuarantaDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN USA.

Funding

Single-Cell Biology and Data Analysis Shared Resource (SCB-DA SR)U54CA217450 · NCI · VANDERBILT UNIVERSITY · PI WEAVER, ALISSA M · 2018 to 2022
$8.5M
Phenotype Transitions in Small Cell Lung CancerU01CA215845 · NCI · VANDERBILT UNIVERSITY · PI LOPEZ, CARLOS FEDERICO, QUARANTA, VITO · 2017 to 2021
$2.8M
Image Driven Multi-Scale Modeling to Predict Treatment Response in Breast CancerU01CA174706 · NCI · VANDERBILT UNIVERSITY · PI QUARANTA, VITO, YANKEELOV, THOMAS E · 2013 to 2018
$2.5M
Research Specialist in Cancer Systems BiologyR50CA243783 · NCI · VANDERBILT UNIVERSITY · PI TYSON, DARREN R · 2019 to 2023
$781k
Uncovering the molecular networks underlying non-genetic heterogeneity in cancer cell populationsK22CA237857 · NCI · UNIVERSITY OF ARKANSAS AT FAYETTEVILLE · PI HARRIS, LEONARD ALFREDO L. · 2020 to 2022
$563k
NCI NIH HHS K22 CA237857NCI NIH HHS R50 CA243783NCI NIH HHS U01 CA174706NCI NIH HHS U01 CA215845NCI NIH HHS U54 CA217450
6 · The paper itself

Abstract

The drug-induced proliferation (DIP) rate is a metric of

Indexed as

Antineoplastic AgentsLuminescenceCell LineHigh-Throughput Screening AssaysHumansAntineoplastic Agentscell viabilitycontinuous assayDIP ratedrug responsedrug screeningquantitative analysisreal-time luminescencesuspension cells

Identifiers

PMID35443861
PMCPMC9037430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.